Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
QGE031 high affinity anti-IgE: Tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist Source: International Congress 2016 – Asthma management Year: 2016
Single and repeat dose safety and pharmacodynamics studies with the selective intranasal TLR7 agonist GSK2245035 Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014
Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016
Safety and tolerability of acute dosing of beta-blockers in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
LATE-BREAKING ABSTRACT: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic response Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014
Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Safety profile and pharmacokinetics of an inhaled GATA-3-specific DNAzyme in a phase Ib study in patients with stable allergic asthma Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
ALX-0962, an anti-IgE Nanobody® with a dual mode of action Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
Chronic dosing effects of propranolol in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Efficacy and safety of 10 day treatment with the CRTh2 antagonist QAV680 evaluated in patients with allergic rhinitis in an environmental exposure chamber Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014
Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
The allergy to insulin about a case treated by montelukast Source: International Congress 2014 – Clinical allergy Year: 2014
The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
The clinical and genetic factors for predicting the response to inhaled corticosteroids Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014